Disputes about scientific and
technical issues relating to current good manufacturing practice
requirements (CGMP) may arise during FDA inspections of
pharmaceutical manufacturers to determine compliance with CGMP
requirements, or during FDA's assessment of corrective actions
undertaken as a result of such inspections. The guidance provides
procedures for raising such disputes to FDA's Office of Regulatory
Affairs (ORA) and center levels and for requesting review by a
dispute resolution (DR) Panel.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.